VACCINE & PROTEIN THERAPEUTICS UNIT

VACCINE & PROTEIN THERAPEUTICS UNIT

The VAKSIN team is currently innovating a novel vaccine platform utilizing organism classified as Generally Regarded As Safe (GRAS). The primary aim is to ensure the vaccine’s availability in developing countries. Our team is dedicated to streamlining the platform’s design, with a focus on creating conveniences. We intend to enhance the vaccine’s stability at room temperature without the need for a cold chain. This approach not only simplifies storage but also aligns with environmentally friendly practices. Our lab also provides opportunities for individuals seeking training or knowledge acquisition in the realm of vaccines. Funded by the Ministry of Higher Education (MOHE) and Ministry of Science, Technology, and Innovation (MOSTI), we successfully developed the vaccine platform against SARS CoV-2, Acinetobacter baumannii, and dengue virus.